Abstract
Transcatheter aortic valve replacement (TAVR) has exploded into medical care for aortic stenosis, thus changing the treatment options for patients. TAVR is currently approved for extreme-risk, high-risk, and intermediate-risk patients with symptomatic severe aortic stenosis, and randomized trials for low-risk patients are underway. This article traces the trajectory of TAVR as a viable option for higher-risk patients and examines current outcomes.
Original language | English (US) |
---|---|
Pages (from-to) | 126-131 |
Number of pages | 6 |
Journal | Methodist DeBakey cardiovascular journal |
Volume | 13 |
Issue number | 3 |
DOIs | |
State | Published - Jul 1 2017 |
Keywords
- SAVR
- TAVR
- expandable valve
- surgical aortic valve replacement
- transcatheter aortic valve replacement
ASJC Scopus subject areas
- Medicine(all)